Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations.
Seidel JA, Otsuka A, Kabashima K. · 2018
Read Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations. by Seidel JA, Otsuka A, Kabashima K. (2018) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc5883082.txt.
Description
Seidel and co-authors review two checkpoint therapies used against cancer. Their review appeared in Frontiers in Oncology. The drugs block PD-1 or CTLA-4, two brakes on immune cells. Melanoma is hard to treat with radiation or chemotherapy. It can, though, provoke strong immune attack. Blocking those brakes has improved outcomes for many patients.
The review explains how each therapy lifts immune restraint. It weighs trial results in melanoma and other cancers. Many patients still fail to respond or later relapse, the authors note. Side effects and limits get full attention. Later sections map future uses and drug pairings. Readers get a clear account of promise and limits alike.
Catalog record
| CREATOR | Seidel JA, Otsuka A, Kabashima K. |
|---|---|
| YEAR | 2018 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 63 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |